GDF-15 (a biomarker for metformin) and the risk of COVID-19: A two-sample Mendelian randomization study.

ABSTRACT:

Background

Regarding the impact of metformin on COVID-19, there are currently varying opinions from multiple studies. Growth differentiation factor 15 (GDF-15) is a biomarker of metformin use and dosage, and we used two-sample Mendelian randomization (MR) to assess the causal effect of GDF-15 (metformin) on COVID-19 susceptibility, hospitalization, and severe COVID-19, thereby guiding the selection of glucose-lowering agents for diabetic patients during the COVID-19 pandemic.

Methods

Two sets of genetic tools were utilized for MR analysis, derived from publicly available genetic data. The first set was GDF-15 genome-wide association study (GWAS) data from a study with 5440 participants, while the second set was COVID-19 GWAS data from the Host Genetics Initiative (HGI) GWAS

SUBMITTER: Wang Y 

PROVIDER: S-EPMC10545159 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature